Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.

By Deepak L. Bhatt, K. Eagle, E. Ohman, A. Hirsch, S. Goto, E. Mahoney, P. Wilson, M. Alberts, Ralph B. D’Agostino, C. Liau and 7 more. Journal of the American Medical Association (JAMA), 2010

711 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/df2b9eec911b1259de28560f550f540af3040872

Citations in the corpus

• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. (2018, neutral): “%] of 2492 vs 56 [2”
• Low-dose colchicine for secondary prevention of cardiovascular disease. (2013, neutral): “ncluding high-dose statins, as evidenced by the low event t ate in the control group (11).”